NUT Carcinoma

For a rare and aggressive disease such as NUT carcinoma, experience matters. At Dana-Farber/Harvard Cancer Center (DF/HCC), our team of experienced NUT carcinoma specialists works together to provide patients with expert, compassionate, and comprehensive care.

Adult Patients

Geoffrey Shapiro, MD, PhD

• Dana-Farber Cancer Institute Physician
• Director, Early Drug Development Center
• Clinical Director, Center for DNA Damage and Repair
• Professor of Medicine, Harvard Medical School

Dr. Shapiro specializes in clinical trials for adult patients with NUT carcinoma.

Michael Cheng, MD

• Dana-Farber Cancer Institute Physician
• Thoracic Oncology Program
• Instructor in Medicine, Harvard Medical School

Dr. Cheng specializes in both standard of care and clinical trial options for adult patients with NUT carcinoma that originated, or is primarily located, in the lung or thoracic/chest cavity.

Christopher Lathan, MD, MS, MPH

• Dana-Farber Cancer Institute Physician
• Medical Director, Dana-Farber Cancer Institute at St. Elizabeth's Medical Center
• Faculty Director for Cancer Care Equity
• Senior Network Physician
• Thoracic Oncology Program
• Assistant Professor of Medicine, Harvard Medical School

Dr. Lathan specializes in standard of care options for adult patients with NUT carcinoma that originated, or is primarily located, in the lung or thoracic/chest cavity.

Glenn J. Hanna, MD

• Dana-Farber Cancer Institute Physician
• Head and Neck Cancer Center
• Assistant Professor of Medicine, Harvard Medical School

Dr. Hanna specializes in both standard of care and clinical trial options for adult patients with NUT carcinoma that originated, or is primarily located, in the head and neck region.

Pediatric Patients

Steven DuBois, MD, MS

• Dana-Farber Cancer Institute Physician
• Director, Experimental Therapeutics
• Senior Physician
• Associate Professor of Pediatrics, Harvard Medical School

Dr. DuBois specializes in both standard of care and clinical trial options for pediatric patients with NUT carcinoma.

Pathology

Christopher French, MD

Our clinical team works closely with Brigham and Women's Hospital pathologist Christopher French, MD, who oversees the International NUT Midline Carcinoma Registry. Dr. French played a pivotal role in the discovery of the NUT fusion oncogene. As a pathologist, Dr. French does not see patients; however, he is a leader in the field and is involved in much of the research surrounding NUT carcinoma. Dr. French is available for pathology consult to assist referring physicians with diagnosis.